Veru Inc. (NASDAQ:VERU) Expected to Earn FY2023 Earnings of $0.01 Per Share

Veru Inc. (NASDAQ:VERUGet Rating) – Investment analysts at Jefferies Financial Group lifted their FY2023 earnings per share estimates for Veru in a research note issued to investors on Monday, April 11th. Jefferies Financial Group analyst C. Howerton now anticipates that the company will earn $0.01 per share for the year, up from their previous forecast of ($0.26). Jefferies Financial Group also issued estimates for Veru’s FY2024 earnings at $0.72 EPS, FY2025 earnings at $1.17 EPS and FY2026 earnings at $3.29 EPS.

Several other research analysts have also commented on VERU. Oppenheimer lifted their price target on shares of Veru from $25.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday. HC Wainwright boosted their target price on shares of Veru from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday. Zacks Investment Research lowered shares of Veru from a “buy” rating to a “hold” rating in a research note on Saturday, February 12th. Finally, TheStreet lowered shares of Veru from a “c-” rating to a “d” rating in a research note on Thursday, February 10th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Veru presently has a consensus rating of “Buy” and a consensus target price of $22.00.

NASDAQ VERU opened at $14.95 on Thursday. Veru has a one year low of $4.34 and a one year high of $17.50. The company has a 50-day simple moving average of $5.96 and a 200-day simple moving average of $6.67. The firm has a market capitalization of $1.20 billion, a PE ratio of -74.75 and a beta of 0.49.

Veru (NASDAQ:VERUGet Rating) last announced its quarterly earnings data on Wednesday, February 9th. The company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.03. Veru had a negative net margin of 26.68% and a negative return on equity of 10.62%. The company had revenue of $14.14 million during the quarter, compared to analyst estimates of $17.24 million. During the same period last year, the business earned ($0.02) EPS.

A number of institutional investors have recently bought and sold shares of VERU. PNC Financial Services Group Inc. raised its position in shares of Veru by 833.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,600 shares of the company’s stock worth $49,000 after buying an additional 5,000 shares in the last quarter. Ensign Peak Advisors Inc bought a new stake in shares of Veru during the 4th quarter worth about $51,000. Citigroup Inc. raised its position in shares of Veru by 81.1% during the 3rd quarter. Citigroup Inc. now owns 9,754 shares of the company’s stock worth $83,000 after buying an additional 4,368 shares in the last quarter. Selective Wealth Management Inc. bought a new stake in shares of Veru during the 3rd quarter worth about $85,000. Finally, Josh Arnold Investment Consultant LLC bought a new stake in shares of Veru during the 4th quarter worth about $59,000. 30.42% of the stock is owned by hedge funds and other institutional investors.

About Veru (Get Rating)

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

Featured Stories

Earnings History and Estimates for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.